Evaluate the pros and cons of using Librela injections versus daily glucosamine supplements for clinic dogs showing early signs of hip dysplasia and joint degeneration.
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Evaluate the pros and cons of using Librela injections versus daily glucosamine supplements for clinic dogs showing early signs of hip dysplasia and joint degeneration.
3 real searches · 1 real-search pass
Librela bedinvetmab FDA safety label canine osteoarthritis adverse events 2025 2026Google ↗
OBSERVEDConsequence
canine osteoarthritis glucosamine chondroitin evidence systematic review randomized trial dogs hip dysplasiaGoogle ↗
OBSERVEDReason
Librela bedinvetmab efficacy canine osteoarthritis randomized controlled trial monthly injectionGoogle ↗
OBSERVEDConsequence
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
ChatGPT real searches (3)
Classes come from the query-classifier (a local Laya model). 3 of 3 calls are low-confidence (under 50%) — hover a query in the table to see its confidence.
Searches and sources
ChatGPT3 real searches · gpt-6
Librela bedinvetmab FDA safety label canine osteoarthritis adverse events 2025 2026 Google ↗
canine osteoarthritis glucosamine chondroitin evidence systematic review randomized trial dogs hip dysplasia Google ↗
Librela bedinvetmab efficacy canine osteoarthritis randomized controlled trial monthly injection Google ↗
- A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody · pubmed.ncbi.nlm.nih.gov
- A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis · pubmed.ncbi.nlm.nih.gov
- Animal Drug Safety-Related Labeling Changes · fda.gov
- Dear Veterinarian Letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection) · fda.gov
- Package Insert for LIBRELA · animaldrugsatfda.fda.gov
- A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis · pmc.ncbi.nlm.nih.gov
- Current evidence for non‐pharmaceutical, non‐surgical treatments of canine osteoarthritis - Pye - 2024 - Journal of Small Animal Practice · doi.org
- Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial · pubmed.ncbi.nlm.nih.gov
- Frontiers | COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis · frontiersin.org
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
Librela bedinvetmab FDA safety label canine osteoarthritis adverse events 2025 2026 OBSERVED | Google ↗ AI Mode ↗ | — | Consequence | — | — | 1x of 1 | |
canine osteoarthritis glucosamine chondroitin evidence systematic review randomized trial dogs hip dysplasia OBSERVED | Google ↗ AI Mode ↗ | — | Reason | — | — | 1x of 1 | |
Librela bedinvetmab efficacy canine osteoarthritis randomized controlled trial monthly injection OBSERVED | Google ↗ AI Mode ↗ | — | Consequence | — | — | 1x of 1 |